買家已把哪些款項寫進申報
中國、台灣、日本、韓國的 40 筆樣本中,14 筆有付款方確認的首付現金,合計 37.145 億美元。這是逐筆可辨認的首付小計,納入付款方明示已付或在完成交割時揭露的現金首付。後續條件款另外記帳。Madrigal 申報已付 Ribocure 在研藥提名款 400 萬美元,石藥公告另外收到開發里程碑 2,500 萬美元。股權與未來付款義務也各有欄位。樣本刻意收錄可找到公開一手條款的交易和少數另行公告的修約。個別交易可以直接對照,各地申報方式、揭露程度和公告時間的差異會影響國別比較。 [D00] [D99] [D15P] [D01R]

石藥從阿斯特捷利康取得 12 億美元,信達從輝瑞取得 6.5 億美元。後者由輝瑞列入營業現金流出。恆瑞與必治妥施貴寶(BMS)的交易也能看出現金與費用的時間差。BMS 已付 6 億美元首付,同季認列另一筆 1.75 億美元不可撤銷的首週年款,預定 2027 年支付。合約另外有 1.75 億美元的第二週年款,須達成條件。 [D01P] [D03P] [D04] [D04P] [D04X]
這張付款表會隨申報更新。默沙東在 9 月完成 SciBrunch 的 SPR2015 全球授權並認列 4 億美元研發費用,申報仍把付款放在第四季。艾伯維把榮昌 RC148 的 6.5 億美元首付列入費用。該附註確認合約與金額,榮昌另在 4 月公告已收足 6.5 億美元,收款單列。小計依付款方現金證據計算。 [D07] [D07P] [D02P] [D02R]
同樣一個頭條金額,買到的權利不同
阿斯特捷利康取得石藥首批計畫在中國內地、香港、澳門和台灣以外的權利,另合作開發新計畫,並保有在中國共同商業化的選擇權。不含權利金的 185 億美元加總上限,由 12 億美元首付、最高 35 億美元開發相關款,以及最高 138 億美元銷售款組成。信達與輝瑞收 6.5 億美元首付,最高 98.5 億美元是里程碑,指定共同開發、共同銷售的計畫在美歐分潤。榮昌與艾伯維公告的 6.5 億美元首付與最高 49.5 億美元里程碑則對應一個具名抗體 RC148,權利範圍在大中華區以外。艾伯維申報把條件款約述為 50 億美元。 [D01] [D01P] [D02] [D02X] [D03] [D03P]

多資產合約的上限可綁在不同計畫、不同適應症上。第一步是弄清哪些選擇權已行使、誰付開發費、原研還握有哪些市場。BMS 與恆瑞約 152 億美元的潛在總包,同時包含恆瑞對外品項、BMS 反向授權與共同探索計畫。單一品項的價格仍須看各份合約,整包只有共同的上限口徑。 [D04] [D04X]
迪哲給了另一個會計對照。阿斯特捷利康在 Zegfrovy 交割後列出 6 億美元現金首付,原本公告的條件款上限是 9 億美元;以收購日的暫定公允價值衡量,條件款為 3.46 億美元,暫列總對價 9.46 億美元。9 億美元描述合約可能要給多少,3.46 億美元反映收購日的會計衡量。 [D05] [D05P] [D05X]

先看買家能在哪裡開發、製造和賣藥
渤健在申報確認已付天境生物 1 億美元首付,取得 felzartamab 在大中華區的權利,並承接既有對 MorphoSys 的部分義務。Travere 在 7 月付給雲頂新耀 1.125 億美元,取得中國與部分東亞、東南亞市場以外的 civorebrutinib 權利,並與雲頂分攤約定的全球開發成本。同樣從中國公司引進藥物,買家負責的市場、成本和歷史義務各有不同。 [D11] [D11P] [D12] [D12P]

日本、韓國的交易也要看現金用途。Mineralys 付給田邊 2 億美元修訂 lorundrostat 原約、買回未來權利金義務。新增的商業里程碑最高 1 億美元;加上原約保留款,剩餘里程碑最高 2.65 億美元。千壽 KIO-401 合約列 350 萬美元首付,以及可部分抵扣後續付款的 1,250 萬美元技轉款。Agios 確認付給 Oscotec 2,500 萬美元,Oscotec 仍可選擇參與韓國開發及商業化。渤健為 Alteogen 的皮下給藥技術協議首付 2,000 萬美元。第二項產品啟動開發後才可能支付的 1,000 萬美元另列。 [D19] [D19X] [D22] [D22P] [D28] [D28P] [D29] [D29P]
股權要獨立記。Avere 的公開說明書確認翰森已收首付 9,000 萬美元,合約首付共 1.2 億美元,剩餘 3,000 萬美元須在合格反向合併交割後支付。文件還列出因授權而發行的優先股,另有一筆用途不同的融資。田邊與 Tolerance Bio 也約定以股權作為部分對價,價值未公開。兩筆股權均未列入首付現金小計。 [D18] [D18P] [D18X] [D20]
台灣的平台授權與區域上市路徑
浩鼎與諾華的合約列 3,000 萬美元首付、逾 20 億美元潛在總額。諾華取得指定未公開載荷所需的浩鼎 ADC 平台技術、專利與專門知識的全球獨家授權。條款由浩鼎在 11 月公開,截至資料截點,付款方實付日期未公開。 [D40] [D40X]

逸達對 Primevera 的交易列 1,000 萬美元首付,保留新公司 19% 股權。依逸達股東會議事手冊,自行開發與商業化路徑下,法規與銷售里程碑合計最高 5.745 億美元,連同首付、不含權利金為 5.845 億美元。英文新聞稿摘要將後一個數字列作里程碑,但內文分項與議事手冊一致。若 Primevera 轉授權,改依合約分享再授權收入。逸達半年報把首付列為現金流入,並在關係人附註把 19% 持股的初始價值列為 779 萬美元。 [D39] [D39X] [D39R]
台灣微脂體將 TLC599 在日本的開發與商業化授予日本臟器。公告列簽約金與各類里程碑合計最高 2.03 億美元,簽約金未單列。台新藥的 APP13007 有三筆,台新藥與 Samil 分別簽下韓國與越南商業化權利,另和 Arrotex 簽澳洲、紐西蘭商業化權利。太景的 Pixavir 與瑩碩的攝護腺用持續釋放口溶錠,也各自藉韓國合作方推進開發與商業化。這些合約各自打通區域通路,並保留未公開的付款條件。 [D32] [D33] [D35] [D36] [D37] [D38]
三個可在下一輪申報對帳的判斷
後續申報將改變實付小計。 每看到一份點名交易的現金流或已交割現金對價,再把款項入帳。簽約承諾與費用認列仍應看得到,讀者才知道哪筆合約已付。默沙東對 SciBrunch 的 4 億美元首付,是近期可對帳的一筆。 [D07P] [D99]
比較首付,要連同買到的權利一起比。 多資產選擇權、保留市場與共同銷售,會改變買家實際取得的控制權。BMS 與恆瑞的總包、阿斯特捷利康與石藥的合作,以及渤健的大中華區授權,各自配置開發責任和收益。 [D01] [D04] [D11]
台灣樣本已經有兩條可追蹤的路徑。 浩鼎和逸達以平台或計畫的全球權利取得有公開金額的簽約金,台新藥與台灣微脂體用區域合作逐一推進不同市場。浩鼎這筆交易的下一次對帳,等付款方申報寫出付款時間。 [D32] [D35] [D36] [D38] [D39] [D40]

逐筆交易表
金額統一為百萬美元。表中「未公開」涵蓋金額未揭露或實付無法核實,各有專欄。已約定首付與已確認付款分列。總包參考值有時包含首付與條件款,另計之權利金依契約口徑保留。公告日與文件日期不同時在資料檔各自保留。下載逐筆交易 CSV。
| 公告日 | 原研地 | 授權方 → 買家/資產 | 權利範圍 | 約定首付 | 付款方已付 | 授權方確認收款 | 條件款/股權 | 來源 |
|---|---|---|---|---|---|---|---|---|
| 2026-01-30 | 中國 | CSPC → AstraZeneca / Cardiometabolic portfolio | 中國內地、香港、澳門及台灣以外獨家;附中國共同商業化選擇權 | 1200 | 1200 | 1200 | 開發及法規款最高35億美元,銷售款最高138億美元;權利金另計 / 里程碑參考 17300 / 總包參考 18500 | [D01] [D01P] [D01R] |
| 2026-01-12 | 中國 | RemeGen → AbbVie / RC148 | 大中華區外獨家開發、生產及商業化 | 650 | 實付未確認 | 650 | 開發、法規及商業里程碑;分級雙位數權利金另計 / 里程碑參考 4950 / 總包參考 5600 | [D02] [D02P] [D02R] |
| 2026-05-28 | 中國 | Innovent → Pfizer / Oncology portfolio | 按計畫分配全球開發與授權;共同開發及商業化計畫於美歐分潤 | 650 | 650 | — | 開發、法規及商業里程碑;依計畫另有權利金或分潤 / 里程碑參考 9850 / 總包參考 10500 | [D03] [D03P] |
| 2026-05-12 | 中國 | Hengrui → Bristol Myers Squibb / Oncology, hematology and immunology portfolio | BMS 取得恆瑞原研計畫的中國內地、香港及澳門以外權利;整包亦含 BMS 原研反向授權 | 600 | 600 | — | 首週年1.75億美元;第二週年1.75億美元附條件;開發、法規與商業里程碑另計 / 總包參考 15200 | [D04] [D04P] |
| 2026-07-14 | 中國 | Dizal → AstraZeneca / Zegfrovy / sunvozertinib | 全球開發及商業化;交割另含支援中國製造的人員及合約 | 600 | 600 | — | 開發、法規及銷售里程碑;權利金另計 / 里程碑參考 900 / 總包參考 1500 | [D05] [D05P] |
| 2026-10-02 | 中國 | Abogen → Novartis / ABO2203 and RNA programs | 主資產全球授權,另含其他 RNA 計畫選擇權 | 575 | 實付未確認 | — | 里程碑約數以所有選擇權行使且達成條件為前提;權利金另計 / 里程碑參考 7200 | [D06] |
| 2026-09-28 | 中國 | SciBrunch → Merck / SPR2015 / MK-2690 | 全球獨家開發、生產及商業化 | 400 | 實付未確認 | — | 多適應症里程碑附條件;付款方預計第四季支付首付 / 里程碑參考 1730 / 總包參考 2130 | [D07] [D07P] |
| 2026-10-19 | 中國 | Hansoh → Roche / ADC programs | 大中華區外;翰森保有部分計畫選擇權與美國收益參與機會 | 400 | 實付未確認 | — | 首週年1.1億美元;潛在里程碑逾150億美元;權利金另計 | [D08] |
| 2026-02-08 | 中國 | Innovent → Eli Lilly / Oncology and immunology collaboration | 禮來主導多數計畫之大中華區外開發;指定計畫另有美國商業參與安排 | 350 | 實付未確認 | — | 開發、法規及商業里程碑;權利金另計 / 里程碑參考 8500 | [D09] |
| 2026-09-29 | 中國 | Hengrui → Novo Nordisk / HRS-1596 | 大中華區外全球獨家 | 300 | 實付未確認 | — | 開發、法規及商業里程碑;權利金另計 / 里程碑參考 2300 / 總包參考 2600 | [D10] |
| 2026-04-20 | 中國 | TJ Biopharma → Biogen / Felzartamab | 按資產購買協議取得大中華區獨家權利 | 100 | 100 | — | 商業款最高2,000萬美元,銷售款最高7.3億美元;另承接 MorphoSys 義務 / 里程碑參考 750 / 總包參考 850 | [D11] [D11P] |
| 2026-06-02 | 中國 | Everest Medicines → Travere / Civorebrutinib / EVER001 | 中國及部分東亞、東南亞市場以外獨家;共同分攤全球試驗成本 | 112.5 | 112.5 | — | 付款方申報將額外里程碑約述為10億美元;權利金另計 / 里程碑參考 1000 | [D12] [D12P] |
| 2026-07-14 | 中國 | Innovent → Spero / SP001 / IBI355 | 大中華區外;信達保留約定的研發或製造活動 | 35 | 35 | — | 開發、法規及商業里程碑;權利金另計 / 里程碑參考 1050 | [D13] [D13P] |
| 2026-06-22 | 中國 | Haisco → Nuvectis / NXP100 / NXP200 | 中國內地、香港、澳門及台灣以外獨家 | 20 | 20 | — | 兩計畫共約14億美元潛在里程碑;權利金另計 / 里程碑參考 1400 | [D14] [D14P] |
| 2026-02-11 | 中國 | Suzhou Ribo / Ribocure → Madrigal / MASH siRNA programs | 授權計畫全球獨家開發、生產及商業化 | 60 | 60 | — | 付款方申報已支付在研藥提名里程碑400萬美元;條件款上限採付款方口徑 / 里程碑參考 4400 | [D15] [D15P] |
| 2026-01-12 | 中國 | Nanjing Hanxin → Amphastar / AMP-110 | 合約約定產品的美國與加拿大獨家權利 | 2 | 2 | — | 開發最高1,400萬美元,銷售最高7,500萬美元;權利金上限另列 / 里程碑參考 89 | [D16] [D16P] |
| 2026-09-03 | 中國 | HUTCHMED → GSK / HMPL-A830 | 中國內地、香港、澳門及台灣以外;另一早期資產附優先議約權 | 110 | 實付未確認 | — | 開發、法規及商業里程碑;權利金另計 / 里程碑參考 1185 / 總包參考 1295 | [D17] |
| 2026-07-14 | 中國 | Hansoh → Avere / AVR-001 / HS-20118 | 大中華區外全球獨家 | 120 | 90 | — | 9,000萬美元按合約期限支付;3,000萬美元視合格反向合併而定;里程碑、權利金另計 / 已發行 15,291,667 股 Seed-1 優先股 | [D18] [D18P] |
| 2026-10-29 | 日本 | Senju → Kiora / KIO-401 | 美洲、歐洲、中東及非洲獨家 | 3.5 | 實付未確認 | — | 技轉款1,250萬美元,部分可抵扣;法規與商業里程碑最高1.685億美元 / 里程碑參考 168.5 | [D19] [D19P] |
| 2026-09-28 | 日本 | Tanabe → Tolerance Bio / TLB-33 / MT-2990 | 全球獨家開發及生產;日本以外獨家商業化 | 未公開 | 實付未確認 | — | 開發及銷售里程碑為約數;權利金另計 / 另約定股權,價值未公開 / 里程碑參考 560 | [D20] |
| 2026-08-18 | 日本 | Tanabe → LEO Pharma / Dersimelagon / MT-7117 | 移轉 EPP 與 XLP 用途的全球開發及商業化權利 | 未公開 | 實付未確認 | — | 首付及近期里程碑合計最高4.35億美元;後續里程碑及權利金另計 | [D21] |
| 2026-06-03 | 日本 | Tanabe → Mineralys / Lorundrostat | 既有授權修約;調整範圍並買回權利金義務 | 200 | 200 | — | 新增銷售里程碑最高1億美元;剩餘里程碑總額2.65億美元含原約保留款 / 里程碑參考 100 | [D22] [D22P] |
| 2026-04-10 | 日本 | SCOHIA → Neurocrine / SCO-483 | 全球獨家開發及商業化 | 20 | 實付未確認 | 20 | 開發及商業里程碑;權利金另計 / 里程碑參考 550 | [D23] [D23R] |
| 2026-01-07 | 日本 | Daiichi Sankyo → GENESIS Pharma / Quizartinib | 指定中東歐市場商業化;第一三共負責製造與供貨 | 未公開 | 實付未確認 | — | 未公開 | [D24] |
| 2026-10-29 | 韓國 | GC Biopharma / Hanmi → BioMarin / HM15421 / GC1134A | 全球獨家開發及商業化;依公告安排 | 70 | 實付未確認 | — | 開發、法規及商業里程碑;權利金另計 | [D25] |
| 2026-10-14 | 韓國 | PinotBio → Alentis / ADC linker and payload technology | 對指定在研藥的連接子或載荷取得獨家授權選擇權 | 未公開 | 實付未確認 | — | 有首付及里程碑但金額未公開;選定在研藥另有權利金 | [D26] |
| 2026-08-24 | 韓國 | Hanmi → Genentech / HM17321 | 韓國以外全球獨家;韓美完成早期劑量遞增工作後由 Genentech 接手 | 190 | 實付未確認 | — | 公司稿列約23億美元,摘要與正文對權利金是否納入的表述有差異 | [D27] |
| 2026-06-01 | 韓國 | Oscotec / Genosco → Agios / Cevidoplenib | 全球權利,Oscotec 保有韓國參與選擇權 | 25 | 25 | — | 付款方列美歐開發及法規款最高1.4億美元,另有銷售款;總包上限由授權方公告 / 總包參考 665 | [D28] [D28P] |
| 2026-03-25 | 韓國 | Alteogen → Biogen / ALT-B4 / Hybrozyme | 指定生物製劑的皮下劑型開發與商業化授權 | 20 | 20 | — | 第二產品啟動開發可再付1,000萬美元;另有里程碑、權利金 / 里程碑參考 549 | [D29] [D29P] |
| 2026-03-24 | 韓國 | Oscotec → Yatiri / Denfivontinib | 急性骨髓性白血病用途之獨家引進選擇權 | 未公開 | 實付未確認 | — | 未公開 | [D30] |
| 2026-01-09 | 韓國 | Prazer → Janssen / SPiDEM degrader platform | 指定靶點的研究與授權合作 | 未公開 | 實付未確認 | — | 未公開 | [D31] |
| 2026-10-05 | 台灣 | TLC BioSciences → Nippon Zoki / TLC599 | 日本獨家開發及商業化 | 未公開 | 實付未確認 | — | 簽約金、開發、法規及銷售款合計;分級權利金另計 / 總包參考 203 | [D32] |
| 2026-09-16 | 台灣 | Anxo → YS Life Science / Extended-release tamsulosin ODT | 韓國獨家開發與銷售 | 未公開 | 實付未確認 | — | 未公開 | [D33] |
| 2026-08-10 | 台灣 | Lumosa → AMED Co., Ltd. / LT1001 | 區域增補,新增阿聯、沙烏地阿拉伯、科威特、阿曼、卡達與巴林 | 未公開 | 實付未確認 | — | 里程碑與權利金視藥證及銷售;金額未公開 | [D34] |
| 2026-06-11 | 台灣 | Formosa Pharmaceuticals → Samil / APP13007 | 越南獨家商業化 | 未公開 | 實付未確認 | — | 含首付、法規與銷售里程碑及權利金;金額未公開 | [D35] |
| 2026-02-23 | 台灣 | Formosa Pharmaceuticals → Arrotex / APP13007 | 澳洲與紐西蘭獨家商業化 | 未公開 | 實付未確認 | — | 含首付、法規與銷售里程碑及權利金;金額未公開 | [D36] |
| 2026-01-26 | 台灣 | TaiGen → Boryung Biopharma / Pixavir marboxil / TG-1000 | 韓國獨家開發及銷售 | 未公開 | 實付未確認 | — | 含首付、里程碑與權利金;金額未公開 | [D37] |
| 2026-01-12 | 台灣 | Formosa Pharmaceuticals → Samil / APP13007 | 韓國獨家商業化 | 未公開 | 實付未確認 | — | 含首付、法規與銷售里程碑及權利金;金額未公開 | [D38] |
| 2026-01-08 | 台灣 | Foresee → Primevera / MMP-12 inhibitor programs | 授權計畫全球獨家 | 10 | 實付未確認 | 10 | 自行商業化路徑之里程碑最高5.745億美元;再授權收入分成可取代里程碑及權利金 / 保留 19% 股權,初始價值 779 萬美元 / 里程碑參考 574.5 / 總包參考 584.5 | [D39] [D39R] |
| 2026-11-13 | 台灣 | OBI Pharma → Novartis / ADC platform | 針對指定未公開載荷,全球獨家授權相關技術、專利及專門知識 | 30 | 實付未確認 | — | 總潛在價值逾20億美元,含開發、法規及商業里程碑 | [D40] |
收錄與更正
資料收錄年初至截點選定的公開合約。區域按原研/授權方歸屬記錄,另保留付款方及授權範圍。香港公司與中港集團列入中國組並保留個別名稱。區域增補、選擇權、現有合約修訂各有類型欄。同一合約包無論涵蓋多少資產、多少共同授權方,均計一筆。只公開合作意向而無具體權利的案子未列入。
若有更正,請提供交易名稱、一手文件、公布日,以及改變金額、範圍或付款狀態的條款或財報附註。本文供產業研究,不構成投資或醫療建議。
常見問題
依付款方申報,2026 亞洲生技對外授權實付首付有多少?
中國、台灣、日本、韓國的 40 筆樣本中,14 筆有付款方確認的首付現金,合計 37.145 億美元。這是逐筆可辨認的首付小計,納入付款方明示已付或在完成交割時揭露的現金首付。後續條件款另外記帳。Madrigal 申報已付 Ribocure 在研藥提名款 400 萬美元,石藥公告另外收到開發里程碑 2,500 萬美元。股權與未來付款義務也各有欄位。樣本刻意收錄可找到公開一手條款的交易和少數另行公告的修約。個別交易可以直接對照,各地申報方式、揭露程度和公告時間的差異會影響國別比較。 [D00] [D99] [D15P] [D01R]
默沙東認列 SciBrunch 的 4 億美元時,現金已經付了嗎?
這張付款表會隨申報更新。默沙東在 9 月完成 SciBrunch 的 SPR2015 全球授權並認列 4 億美元研發費用,申報仍把付款放在第四季。艾伯維把榮昌 RC148 的 6.5 億美元首付列入費用。該附註確認合約與金額,榮昌另在 4 月公告已收足 6.5 億美元,收款單列。小計依付款方現金證據計算。 [D07] [D07P] [D02P] [D02R]
石藥、信達和榮昌的授權頭條價各買到什麼?
阿斯特捷利康取得石藥首批計畫在中國內地、香港、澳門和台灣以外的權利,另合作開發新計畫,並保有在中國共同商業化的選擇權。不含權利金的 185 億美元加總上限,由 12 億美元首付、最高 35 億美元開發相關款,以及最高 138 億美元銷售款組成。信達與輝瑞收 6.5 億美元首付,最高 98.5 億美元是里程碑,指定共同開發、共同銷售的計畫在美歐分潤。榮昌與艾伯維公告的 6.5 億美元首付與最高 49.5 億美元里程碑則對應一個具名抗體 RC148,權利範圍在大中華區以外。艾伯維申報把條件款約述為 50 億美元。 [D01] [D01P] [D02] [D02X] [D03] [D03P]
浩鼎授權諾華的範圍與首付是什麼?
浩鼎與諾華的合約列 3,000 萬美元首付、逾 20 億美元潛在總額。諾華取得指定未公開載荷所需的浩鼎 ADC 平台技術、專利與專門知識的全球獨家授權。條款由浩鼎在 11 月公開,截至資料截點,付款方實付日期未公開。 [D40] [D40X]
逸達在 Primevera 案保留什麼,里程碑上限多少?
逸達對 Primevera 的交易列 1,000 萬美元首付,保留新公司 19% 股權。依逸達股東會議事手冊,自行開發與商業化路徑下,法規與銷售里程碑合計最高 5.745 億美元,連同首付、不含權利金為 5.845 億美元。英文新聞稿摘要將後一個數字列作里程碑,但內文分項與議事手冊一致。若 Primevera 轉授權,改依合約分享再授權收入。逸達半年報把首付列為現金流入,並在關係人附註把 19% 持股的初始價值列為 779 萬美元。 [D39] [D39X] [D39R]
References
- D00
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hkexnews.hk) | | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0130/2026013000101.pdf
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (news.abbvie.com) | | https://news.abbvie.com/2026-01-12-AbbVie-and-RemeGen-Announce-Exclusive-Licensing-Agreement-to-Develop-A-Novel-Bispecific-Antibody-for-Advanced-Solid-Tumors
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (pfizer.com) | | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-innovent-biologics-enter-global-strategic
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hengrui.com) | | https://www.hengrui.com/en/media/detail-951.html
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (abogenbio.com) | | https://www.abogenbio.com/news/company/news2026/277.html
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (merck.com) | | https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-with-scibrunch-therapeutics-for-spr2015-an-investigational-oral-kras-g12d-on-inhibitor/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hspharm.com) | | https://www.hspharm.com/news/news-detail-513518.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (prnewswire.com) | | https://www.prnewswire.com/news-releases/innovent-announces-strategic-collaboration-with-lilly-to-develop-new-medicines-globally-in-oncology-and-immunology-302682009.html
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hengrui.com) | | https://www.hengrui.com/en/media/detail-1042.html
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/d320658d8k.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/tm2618439d1_8k.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1157601/000162828026069145/R18.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (nasdaq.com) | | https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor SEC exhibit (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1648257/000164825726000057/hcm-20260903xex99d1.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926123934/tm2623032-12_424b3.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (ir.kiorapharma.com) | | https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000088/kprx-20261023.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (tolerancebio.com) | | https://www.tolerancebio.com/recent-news/tolerance-bio-licenses-clinical-stage-anti-il-33-monoclonal-antibody-from-tanabe-pharma-to-expand-thymus-focused-clinical-pipeline
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (us.tanabe-pharma.com) | | https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-enters-into-agreement-with-leo-pharma-for-mt-7117-for-epp-and-xlp
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (ir.mineralystx.com) | | https://ir.mineralystx.com/sec-filings/all-sec-filings/content/0001628280-26-040024/mlys-20260602.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (scohia.com) | | https://www.scohia.com/eng/sys/news/260410en/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (genesispharma.com) | | https://www.genesispharma.com/newsroom/news/daiichi-sankyo-and-genesis-pharma-enter-exclusive-agreement-for-quizartinib-commercialization-in-central-eastern-europe/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (investors.biomarin.com) | | https://investors.biomarin.com/news/news-details/2026/BioMarin-Enters-Into-Exclusive-Worldwide-License-Agreement-With-GC-Biopharma-and-Hanmi-Pharm-for-Investigational-Next-Generation-Enzyme-Replacement-Therapy-Adding-a-Second-Potential-Treatment-for-Fabry-Disease/default.aspx
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (alentis.ch) | | https://alentis.ch/alentis-and-pinotbio-announce-collaboration-to-develop-next-generation-adcs-targeting-claudin-1/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hanmipharm.com) | | https://www.hanmipharm.com/about/investor-relations/press/detail-4843.hm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (oscotec.com) | | https://oscotec.com/archives/394656
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (en.prnasia.com) | | https://en.prnasia.com/releases/global/alteogen-enters-into-a-license-agreement-with-biogen-for-development-and-commercialization-of-hybrozyme-based-subcutaneous-biologics-526696.shtml
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (yatiribio.com) | | https://yatiribio.com/2026/03/24/yatiri-bio-enters-exclusive-option-to-in-license-agreement-with-oscotec-for-denfivontinib-in-aml/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (prazertx.com) | | https://prazertx.com/pages/board/view.php?board_sid=16&category_code1=&data_sid=278&menu_code=477&page_num=&skey=&sval=
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=152833&spoke_date=20261005&co_id=7924&TYPEK=rotc
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (anxo.com.tw) | | https://www.anxo.com.tw/news/view/231
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=5&spoke_time=180917&spoke_date=20260810&co_id=6535&TYPEK=otc
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/%E5%8F%B0%E6%96%B0%E8%97%A5%E5%AE%A3%E5%B8%83%E8%88%87samil-pharmaceutical-%E7%B0%BD%E7%BD%B2%E6%8E%88%E6%AC%8A%E5%8D%94%E8%AD%B0%EF%BC%8C%E6%8E%A8%E5%8B%95%E7%9C%BC%E9%83%A8%E8%A1%93%E5%BE%8C/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-arrotex-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-sur/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (taigenbiotech.com) | | https://www.taigenbiotech.com/en/news/detail/226
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-samil-pharmaceuticals-co-ltd-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-p/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (foreseepharma.com) | | https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_global_licensing_agreement_for_mmp_12_inhibitors_with_primevera_therapeutics_llc?page=1
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (obipharma.com) | | https://www.obipharma.com/zh-hant/news/signs-collaboration-and-license-agreement-with-novartis/
- D01
- 2026-01-30 · Cardiometabolic portfolio | licensor disclosure (hkexnews.hk) | | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0130/2026013000101.pdf
- D01P
- Upfront paid US$m 1200; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
- D01R
- Licensor confirms upfront receipt US$m 1200; other cash US$m 25 | licensor receipt (www1.hkexnews.hk) | | https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1118/2026111800389.pdf
- D01X
- US$1.2bn received on May 29 | licensor exchange receipt (hkexnews.hk) | | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0529/2026052902358.pdf
- D02
- 2026-01-12 · RC148 | payer or joint release (news.abbvie.com) | | https://news.abbvie.com/2026-01-12-AbbVie-and-RemeGen-Announce-Exclusive-Licensing-Agreement-to-Develop-A-Novel-Bispecific-Antibody-for-Advanced-Solid-Tumors
- D02P
- Upfront paid US$m unverified; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm
- D02R
- Licensor confirms upfront receipt US$m 650; other cash US$m not specified | licensor receipt (hkexnews.hk) | | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0415/2026041500526.pdf
- D02X
- US$650m recorded in Q1; US$5.0bn rounded contingent amount in the payer filing | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm
- D03
- 2026-05-28 · Oncology portfolio | payer or joint release (pfizer.com) | | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-innovent-biologics-enter-global-strategic
- D03P
- Upfront paid US$m 650; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm
- D04
- 2026-05-12 · Oncology, hematology and immunology portfolio | licensor disclosure (hengrui.com) | | https://www.hengrui.com/en/media/detail-951.html
- D04P
- Upfront paid US$m 600; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm
- D04X
- US$600m paid; US$175m noncancellable anniversary payment for 2027 | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm
- D05
- 2026-07-14 · Zegfrovy / sunvozertinib | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
- D05P
- Upfront paid US$m 600; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm
- D05X
- US$946m provisional fair value: $600m upfront and $346m contingent fair value | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm
- D06
- 2026-10-02 · ABO2203 and RNA programs | licensor disclosure (abogenbio.com) | | https://www.abogenbio.com/news/company/news2026/277.html
- D07
- 2026-09-28 · SPR2015 / MK-2690 | payer or joint release (merck.com) | | https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-with-scibrunch-therapeutics-for-spr2015-an-investigational-oral-kras-g12d-on-inhibitor/
- D07P
- Upfront paid US$m unverified; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm
- D08
- 2026-10-19 · ADC programs | licensor disclosure (hspharm.com) | | https://www.hspharm.com/news/news-detail-513518.htm
- D09
- 2026-02-08 · Oncology and immunology collaboration | licensor disclosure (prnewswire.com) | | https://www.prnewswire.com/news-releases/innovent-announces-strategic-collaboration-with-lilly-to-develop-new-medicines-globally-in-oncology-and-immunology-302682009.html
- D10
- 2026-09-29 · HRS-1596 | licensor disclosure (hengrui.com) | | https://www.hengrui.com/en/media/detail-1042.html
- D11
- 2026-04-20 · Felzartamab | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm
- D11P
- Upfront paid US$m 100; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm
- D12
- 2026-06-02 · Civorebrutinib / EVER001 | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- D12P
- Upfront paid US$m 112.5; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- D13
- 2026-07-14 · SP001 / IBI355 | payer or joint release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/d320658d8k.htm
- D13P
- Upfront paid US$m 35; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm
- D14
- 2026-06-22 · NXP100 / NXP200 | payer or joint release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/tm2618439d1_8k.htm
- D14P
- Upfront paid US$m 20; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1875558/000110465926122387/tmb-20260930x10q.htm
- D15
- 2026-02-11 · MASH siRNA programs | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1157601/000162828026069145/R18.htm
- D15P
- Upfront paid US$m 60; other paid US$m 4 | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1157601/000162828026069145/R18.htm
- D16
- 2026-01-12 · AMP-110 | payer or joint release (nasdaq.com) | | https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin
- D16P
- Upfront paid US$m 2; other paid US$m not specified | payer filing or issuer release (nasdaq.com) | | https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin
- D17
- 2026-09-03 · HMPL-A830 | licensor SEC exhibit (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1648257/000164825726000057/hcm-20260903xex99d1.htm
- D18
- 2026-07-14 · AVR-001 / HS-20118 | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926123934/tm2623032-12_424b3.htm
- D18P
- Upfront paid US$m 90; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926123934/tm2623032-12_424b3.htm
- D18X
- US$120m split 90/30 | payer contract exhibit (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926112469/nxtc-ex10d53.htm
- D19
- 2026-10-29 · KIO-401 | payer or joint release (ir.kiorapharma.com) | | https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000088/kprx-20261023.htm
- D19P
- Upfront paid US$m unverified; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1372514/000137251426000092/kprx-20260930.htm
- D19X
- $12.5m technology-transfer milestone | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1372514/000137251426000092/kprx-20260930.htm
- D20
- 2026-09-28 · TLB-33 / MT-2990 | payer or joint release (tolerancebio.com) | | https://www.tolerancebio.com/recent-news/tolerance-bio-licenses-clinical-stage-anti-il-33-monoclonal-antibody-from-tanabe-pharma-to-expand-thymus-focused-clinical-pipeline
- D21
- 2026-08-18 · Dersimelagon / MT-7117 | licensor disclosure (us.tanabe-pharma.com) | | https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-enters-into-agreement-with-leo-pharma-for-mt-7117-for-epp-and-xlp
- D22
- 2026-06-03 · Lorundrostat | payer or joint release (ir.mineralystx.com) | | https://ir.mineralystx.com/sec-filings/all-sec-filings/content/0001628280-26-040024/mlys-20260602.htm
- D22P
- Upfront paid US$m 200; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm
- D23
- 2026-04-10 · SCO-483 | licensor disclosure (scohia.com) | | https://www.scohia.com/eng/sys/news/260410en/
- D23R
- Licensor confirms upfront receipt US$m 20; other cash US$m not specified | licensor receipt (scohia.com) | | https://www.scohia.com/eng/sys/news/260410en/
- D24
- 2026-01-07 · Quizartinib | payer or joint release (genesispharma.com) | | https://www.genesispharma.com/newsroom/news/daiichi-sankyo-and-genesis-pharma-enter-exclusive-agreement-for-quizartinib-commercialization-in-central-eastern-europe/
- D25
- 2026-10-29 · HM15421 / GC1134A | payer or joint release (investors.biomarin.com) | | https://investors.biomarin.com/news/news-details/2026/BioMarin-Enters-Into-Exclusive-Worldwide-License-Agreement-With-GC-Biopharma-and-Hanmi-Pharm-for-Investigational-Next-Generation-Enzyme-Replacement-Therapy-Adding-a-Second-Potential-Treatment-for-Fabry-Disease/default.aspx
- D26
- 2026-10-14 · ADC linker and payload technology | payer or joint release (alentis.ch) | | https://alentis.ch/alentis-and-pinotbio-announce-collaboration-to-develop-next-generation-adcs-targeting-claudin-1/
- D27
- 2026-08-24 · HM17321 | licensor disclosure (hanmipharm.com) | | https://www.hanmipharm.com/about/investor-relations/press/detail-4843.hm
- D28
- 2026-06-01 · Cevidoplenib | licensor disclosure (oscotec.com) | | https://oscotec.com/archives/394656
- D28P
- Upfront paid US$m 25; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1439222/000143922226000118/agio-20260630.htm
- D29
- 2026-03-25 · ALT-B4 / Hybrozyme | licensor disclosure (en.prnasia.com) | | https://en.prnasia.com/releases/global/alteogen-enters-into-a-license-agreement-with-biogen-for-development-and-commercialization-of-hybrozyme-based-subcutaneous-biologics-526696.shtml
- D29P
- Upfront paid US$m 20; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260630.htm
- D30
- 2026-03-24 · Denfivontinib | payer or joint release (yatiribio.com) | | https://yatiribio.com/2026/03/24/yatiri-bio-enters-exclusive-option-to-in-license-agreement-with-oscotec-for-denfivontinib-in-aml/
- D31
- 2026-01-09 · SPiDEM degrader platform | licensor disclosure (prazertx.com) | | https://prazertx.com/pages/board/view.php?board_sid=16&category_code1=&data_sid=278&menu_code=477&page_num=&skey=&sval=
- D32
- 2026-10-05 · TLC599 | licensor disclosure (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=152833&spoke_date=20261005&co_id=7924&TYPEK=rotc
- D33
- 2026-09-16 · Extended-release tamsulosin ODT | licensor disclosure (anxo.com.tw) | | https://www.anxo.com.tw/news/view/231
- D34
- 2026-08-10 · LT1001 | licensor disclosure (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=5&spoke_time=180917&spoke_date=20260810&co_id=6535&TYPEK=otc
- D35
- 2026-06-11 · APP13007 | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/%E5%8F%B0%E6%96%B0%E8%97%A5%E5%AE%A3%E5%B8%83%E8%88%87samil-pharmaceutical-%E7%B0%BD%E7%BD%B2%E6%8E%88%E6%AC%8A%E5%8D%94%E8%AD%B0%EF%BC%8C%E6%8E%A8%E5%8B%95%E7%9C%BC%E9%83%A8%E8%A1%93%E5%BE%8C/
- D36
- 2026-02-23 · APP13007 | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-arrotex-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-sur/
- D37
- 2026-01-26 · Pixavir marboxil / TG-1000 | licensor disclosure (taigenbiotech.com) | | https://www.taigenbiotech.com/en/news/detail/226
- D38
- 2026-01-12 · APP13007 | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-samil-pharmaceuticals-co-ltd-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-p/
- D39
- 2026-01-08 · MMP-12 inhibitor programs | licensor disclosure (foreseepharma.com) | | https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_global_licensing_agreement_for_mmp_12_inhibitors_with_primevera_therapeutics_llc?page=1
- D39R
- US$10m cash proceeds; NT$316.473m investing inflow; 19% equity initially valued at US$7.79m | licensor interim financial statements (foreseepharma.com) | | https://www.foreseepharma.com/uploads/images/%28%E5%A5%97%E5%8D%B0%29%E9%80%B8%E9%81%94%E7%94%9F%E6%8A%80_2026%E5%90%88%E4%BD%B5%E7%AC%AC%E4%BA%8C%E5%AD%A3_20260630_FS_AllReport_CHT.pdf
- D39X
- US$10m upfront; $214.5m regulatory + $360m sales = $574.5m milestones; $584.5m combined; 19% equity | licensor shareholder circular (foreseepharma.com) | | https://www.foreseepharma.com/uploads/images/114%E5%B9%B4%E8%82%A1%E6%9D%B1%E8%87%A8%E6%99%82%E6%9C%83%E8%AD%B0%E4%BA%8B%E6%89%8B%E5%86%8A%28%E4%B8%AD%E6%96%87%29_20251128_Final.pdf
- D40
- 2026-11-13 · ADC platform | licensor disclosure (obipharma.com) | | https://www.obipharma.com/zh-hant/news/signs-collaboration-and-license-agreement-with-novartis/
- D40X
- 2026-11-13 public announcement; $30m upfront; total potential value above $2bn | licensor MOPS filing (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=3&spoke_time=171730&spoke_date=20261113&co_id=4174&TYPEK=otc
- D99
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1875558/000110465926122387/tmb-20260930x10q.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1157601/000162828026069145/R18.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (nasdaq.com) | | https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926123934/tm2623032-12_424b3.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1439222/000143922226000118/agio-20260630.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260630.htm